Evidence map›Paper›PMID 34844871›Full record

SynthesisInternational immunopharmacology2022

Impact of asthma on COVID-19 mortality in the United States: Evidence based on a meta-analysis.

Xueya Han, Jie Xu, Hongjie Hou, Haiyan Yang, Yadong Wang

Open access · greenAbstract readMeta-AnalysisReview

In one paragraph

Synthesis in International immunopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it

0cells of the map it votes in

8citing papers in PubMed, 3 pooled it

0.8field-weighted citation impact, top 23% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression.Scientific reports · 2023
Pooled it
Interstitial lung disease independently associated with higher risk for COVID-19 severity and mortality: A meta-analysis of adjusted effect estimates.International immunopharmacology · 2022
Pooled it
Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis.PloS one · 2022
Pooled it
Characterizing the Association Between Asthma and Clinical Outcomes in Emergency Department Patients With Symptomatic COVID-19.Cureus · 2025
Article
Platelet Indices as Novel Surrogate Markers for the Prognosis of COVID-19 Infection: An Observational Study.Cureus · 2024
Article
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.Viruses · 2023
Review
A Machine Learning Model for Predicting Hospitalization in Patients with Respiratory Symptoms during the COVID-19 Pandemic.Journal of clinical medicine · 2022
Article
Acceptance Rates of COVID-19 Vaccine Highlight the Need for Targeted Public Health Interventions.Vaccines · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xueya HanDepartment of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China.

Jie XuDepartment of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China.

Hongjie HouDepartment of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China.

Haiyan YangDepartment of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China. Electronic address: yhy@zzu.edu.cn.

Yadong WangDepartment of Toxicology, Henan Center for Disease Control and Prevention, Zhengzhou 450016, Henan Province, China.

Zhengzhou University · CNHenan Provincial Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate the impact of asthma on the risk for mortality among coronavirus disease 2019 (COVID-19) patients in the United States by a quantitative meta-analysis.

methodsA random-effects model was used to estimate the pooled odds ratio (OR) with corresponding 95% confidence interval (CI). I

resultsThe data based on 56 studies with 426,261 COVID-19 patients showed that there was a statistically significant association between pre-existing asthma and the reduced risk for COVID-19 mortality in the United States (OR: 0.82, 95% CI: 0.74-0.91). Subgroup analyses by age, male proportion, sample size, study design and setting demonstrated that pre-existing asthma was associated with a significantly reduced risk for COVID-19 mortality among studies with age ≥ 60 years old (OR: 0.79, 95% CI: 0.72-0.87), male proportion ≥ 55% (OR: 0.79, 95% CI: 0.72-0.87), male proportion ＜ 55% (OR: 0.81, 95% CI: 0.69-0.95), sample sizes ≥ 700 cases (OR: 0.80, 95% CI: 0.71-0.91), retrospective study/case series (OR: 0.82, 95% CI: 0.75-0.89), prospective study (OR: 0.83, 95% CI: 0.70-0.98) and hospitalized patients (OR: 0.82, 95% CI: 0.74-0.91). Meta-regression did reveal none of factors mentioned above were possible reasons of heterogeneity. Sensitivity analysis indicated the robustness of our findings. No publication bias was detected in Begg's test (P = 0.4538).

conclusionOur findings demonstrated pre-existing asthma was significantly associated with a reduced risk for COVID-19 mortality in the United States.

Indexed as

AsthmaCOVID-19HumansPrevalenceProspective StudiesProtective FactorsRetrospective StudiesSARS-CoV-2United StatesAsthmaCOVID-19Meta-analysisMortalityUSA

Identifiers

PMID34844871

DOI10.1016/j.intimp.2021.108390

PMCPMC8611693

OpenAlexW3216699943

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.